Home/Pipeline/Undisclosed (Obesity/Metabolic)

Undisclosed (Obesity/Metabolic)

Obesity/Metabolic Disorders

Phase 2Active

Key Facts

Indication

Obesity/Metabolic Disorders

Phase

Phase 2

Status

Active

Company

SanegeneBio

About SanegeneBio

SanegeneBio is a private, global biotech leveraging its proprietary LEAD™ technology to develop RNAi therapies targeting obesity, cardiometabolic, and autoimmune diseases. The company has advanced multiple programs into clinical trials, supported by over $150 million in funding, and operates R&D centers in both the US and China. Its strategy centers on expanding RNAi beyond liver targets to address large patient populations with chronic conditions through tissue-specific delivery and optimized payloads.

View full company profile

Therapeutic Areas

Metabolic Diseases Obesity Autoimmune Diseases Cardiovascular Diseases

Other Obesity/Metabolic Disorders Drugs

Drug	Company	Phase	Status
GLP1R Agonist	Ambrosia Biosciences	Preclinical	Active
GIPR Antagonist	Ambrosia Biosciences	Discovery	Active
Amylin Agonist	Ambrosia Biosciences	Discovery	Active